CITY-OF-TAMPERE
12.5.2022 07:31:08 CEST | Business Wire | Press release
Tampere’s target is ambitious, but understandable, considering the premium event facilities, unparalleled traditions, and a devoted city community helping Finland’s Home of Hockey in its bold aspirations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005532/en/
- This is everyone’s effort. This is the moment the whole city community has been waiting for. If there were Oscars for the event cities, our performance at 2022 IIHF Ice Hockey World Championship would win by a mile. And a half, says Perttu Pesä, the Director of Major Events at City of Tampere.
Hockey hype in Tampere is at all-time high with local teams Tappara and Ilves winning gold and bronze medals in Finnish league.
Furthermore, the games have taken place at brand-new Nokia Arena, Europe’s leading entertainment venue.
- Tampere has been a true hockey heaven throughout the spring, Atmosphere at Nokia Arena has been amazing, and we will take it to the next level together with our international friends from all over the world, says Anna-Kaisa Ikonen, Mayor of Tampere.
Tampere’s persistent work with major events, sustainability, equality, and smart city development will be the cornerstones of a successful tournament.
City offers free public transport for the game ticket holders and has provided close to 7000 tickets to specified groups, such as senior citizens and school children. Free-of-charge activity zone in the city center is open for all ages and welcomes families to try different sports activities.
Additionally, the unique smart event security solutions enable visitors to enjoy a smooth event experience during their stay.
On ice, Team Finland has a serious chance of writing history in its home tournament. After winning Olympic gold in Beijing, conquering the World Championship would make Finland the first nation to complete the double on home ice.
Links:
Free public transport : https://www.nysse.fi/en/events/ice-hockey-world-championship-2022.html
Finnish Hockey Hall of Fame: https://2022jaakiekonmmkisat.tampere.fi/en/news/renewed-hockey-hall-of-fame-finland-opened-on-april-1-2022/
Smart event security: https://2022jaakiekonmmkisat.tampere.fi/en/news/tampere-sets-the-bar-in-smart-event-security-at-ice-hockey-world-championship/
Tickets for specified groups: https://2022jaakiekonmmkisat.tampere.fi/en/news/tampere-builds-ice-hockey-world-championships-for-all-citizens/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005532/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom